Global Viral Vectors And Plasmid DNA Manufacturing Market By Vector Type (Adenovirus, Retrovirus, Adeno-Associated Virus (AAV), Lentivirus, Plasmids, Others), By Applications (Antisense & RNAi Therapy, Gene Therapy, Cell Therapy, Vaccinology, Research Applications), By Disease (Cancer, Genetic Disorders, Infectious Diseases, Others), By End-Use (Pharmaceutical and Biopharmaceutical Companies, Research Institutes) By Region (North America, Latin America, Europe, Asia Pacific, Middle East and Africa) - Industry Trends and Forecast to 2030.
Global Viral Vectors And Plasmid DNA Manufacturing Market
The Viral Vectors And Plasmid DNA Manufacturing market was valued at USD 5.33 billion in 2022 and is expected to reach USD 19.50 billion by 2030, with a CAGR of 17.26 % during the forecast period 2023-2030.
Plasmid DNA and viral vectors are methods for introducing genetic material into cells. Typically, viral vectors are used as gene therapy vectors. There are many different kinds of vectors, including herpes simplex virus and chimeric viral vectors. These include lentivirus, adenovirus, and adeno-associated virus (AAV). Additionally used as a vector in gene therapy and vaccination, plasmid DNA. There are many different viral vectors that are created using plasmid DNA as their basic material.
Drivers
The development of innovative gene therapies is strongly dependent on high-quality viral vectors and plasmid DNA, which is one of the key reasons driving the market. Additionally, advancements in manufacturing techniques have made it possible to generate viral vectors and plasmid DNA at higher volumes more successfully, while also lowering prices and raising general quality.
Impact of COVID-19
As viral vector-based vaccines may be produced and created reasonably fast with the use of the same building blocks, the ongoing COVID-19 pandemic has prompted investment in this area in quest of a vaccine. Examples of organizations that have created viral vector-based vaccinations include Johnson and Johnson/Janssen (J&J), AstraZeneca/University of Oxford, Gamaleya Research Institute, and CanSino Biologics.
Market Segmentation
Global Viral Vectors And Plasmid DNA Manufacturing Market is segmented into By Vector Type, By Applications, By Disease, By End-Use.
Based on the By Vector Type market is segmented into Adenovirus, Retrovirus, Adeno-Associated Virus (AAV), Lentivirus, Plasmids, Others. Further market is segmented into By Applications market is segmented into Antisense & RNAi Therapy, Gene Therapy, Cell Therapy, Vaccinology, Research Applications. By Disease market is segmented into Cancer, Genetic Disorders, Infectious Diseases, Others. By End-Use market is segmented into Pharmaceutical and Biopharmaceutical Companies, Research Institutes.
Regional Analysis
Global Viral Vectors And Plasmid DNA Manufacturing Market is segmented into five main regions, namely, North America, Europe, Asia Pacific, Middle East and Africa, and Latin America. North America dominates the Viral Vectors And Plasmid DNA Manufacturing market. The existence of a sizable number of centers and institutes involved in the R&D of advanced medicines is one of the key factors that has contributed to the huge share of this regional market. The federal agencies' investments in the region's cell therapy research base are expected to boost the market's expansion in North America.
Key Players.
Various key players are listed in this report such as Merck KGaA, FUJIFILM Diosynth Biotechnologies, Thermo Fisher Scientific, Catalent Inc., Wuxi Biologics, Takara Bio Inc., Waisman Biomanufacturing, Genezen laboratories, Batavia Biosciences, Miltenyi Biotec GmbH.
Market Taxonomy
By Vector Type
• Adenovirus
• Retrovirus
• Adeno-Associated Virus (AAV)
• Lentivirus
• Plasmids
• Others
By Applications
• Antisense & RNAi Therapy
• Gene Therapy
• Cell Therapy
• Vaccinology
• Research Applications
By Disease
• Cancer
• Genetic Disorders
• Infectious Diseases
• Others
By End-Use
• Pharmaceutical and Biopharmaceutical Companies
• Research Institutes
By Region
• North America
o U.S.
o Canada
o Mexico
• Latin America
o Brazil
o Argentina
o Colombia
o Peru
o Chile
o Venezuela
o Rest of Latin America
• Europe
o Germany
o France
o UK
o Russia
o Italy
o Spain
o Rest of Europe
• Asia Pacific
o China
o Japan
o India
o South Korea
o Australia
o New Zealand
o Singapore
o Malaysia
o Rest of Asia Pacific
• Middle East & Africa
o Saudi Arabia
o UAE
o Egypt
o Kuwait
o South Africa
o Rest Middle East & Africa
Key Questions Addressed by the Report
• What are the Key Opportunities in Global Viral Vectors And Plasmid DNA Manufacturing Market?
• What will be the growth rate from 2023 to 2030?
• Which segment/region will have highest growth?
• What are the factors that will impact/drive the Market?
• What is the competitive Landscape in the Industry?
• What is the role of key players in the value chain?
Global Viral Vectors And Plasmid DNA Manufacturing Market
1 Introduction
1.1 Objective of the Study
1.2 Market definition
1.3 Market Scope
2 Research Methodology
2.1 Data Mining
2.2 Validation
2.3 Primary Interviews
2.4 List of Data Sources
3 Executive Summary
4 Global Viral Vectors And Plasmid DNA Manufacturing Market Outlook
4.1 Overview
4.2 Market Dynamics
4.2.1 Drivers
4.2.2 Restraints
4.2.3 Opportunities
4.2.4Cumulative Impact due to recent Energy Crisis
4.2.5 Cumulative Impact due to nearing Economic Downturn
4.2.6 Post Covid-19 World supply and Demand Condition
4.2.7 Cumulative Impact of Russia Ukraine Conflict
4.3 Porters Five Force Model
4.4 Value Chain Analysis
5 Global Viral Vectors And Plasmid DNA Manufacturing Market, By Vector Type
5.1 Y-o-Y Growth Comparison, By Vector Type
5.2 Global Viral Vectors And Plasmid DNA Manufacturing Market Share Analysis, By Vector Type
5.3 Global Viral Vectors And Plasmid DNA Manufacturing Market Size and Forecast, By Vector Type
5.3.1 Adenovirus
5.3.2 Retrovirus
5.3.3 Adeno-Associated Virus (AAV)
5.3.4 Lentivirus
5.3.5 Plasmids
5.3.5 Others
6 Global Viral Vectors And Plasmid DNA Manufacturing Market, By Applications
6.1 Y-o-Y Growth Comparison, By Applications
6.2 Global Viral Vectors And Plasmid DNA Manufacturing Market Share Analysis, By Applications
6.3 Global Viral Vectors And Plasmid DNA Manufacturing Market Size and Forecast, By Applications
6.3.1 Antisense & RNAi Therapy
6.3.2 Gene Therapy
6.3.3 Cell Therapy
6.3.4 Vaccinology
6.3.5 Research Applications
7 Global Viral Vectors And Plasmid DNA Manufacturing Market, By Disease
7.1 Y-o-Y Growth Comparison, By Disease
7.2 Global Viral Vectors And Plasmid DNA Manufacturing Market Share Analysis, By Disease
7.3 Global Viral Vectors And Plasmid DNA Manufacturing Market Size and Forecast, By Disease
7.3.1 Cancer
7.3.2 Genetic Disorders
7.3.3 Infectious Diseases
7.3.4 Others
8 Global Viral Vectors And Plasmid DNA Manufacturing Market, By End-Use
8.1 Y-O-Y Growth Comparison, By End-Use
8.2 Global Viral Vectors And Plasmid DNA Manufacturing Market Share Analysis, By End-Use
8.3 Global Viral Vectors And Plasmid DNA Manufacturing Market Size and Forecast, By End-Use
8.3.1 Pharmaceutical and Biopharmaceutical Companies
8.3.2 Research Institutes
9 Global Viral Vectors And Plasmid DNA Manufacturing Market, By Region
9.1 Global Viral Vectors And Plasmid DNA Manufacturing Market Share Analysis, By Region
9.2 Global Viral Vectors And Plasmid DNA Manufacturing Market Size and Forecast, By Region
9.3 Global Viral Vectors And Plasmid DNA Manufacturing Market Trends and Forecast, By Region
10 North America Viral Vectors And Plasmid DNA Manufacturing Market Analysis and Forecast (2023-2030)
10.1 Introduction
10.2 North America Viral Vectors And Plasmid DNA Manufacturing Market Share Analysis, By Vector Type
10.3 North America Viral Vectors And Plasmid DNA Manufacturing Market Size and Forecast, By Applications
10.4 North America Viral Vectors And Plasmid DNA Manufacturing Market Size and Forecast, By Disease
10.5 North America Viral Vectors And Plasmid DNA Manufacturing Market Size and Forecast, By End-Use
10.6 North America Viral Vectors And Plasmid DNA Manufacturing Market Size and Forecast, By Country
10.6.1 U.S.
10.6.1.1. Market Size and Forecast, By Vector Type
10.6.1.2 Market Size and Forecast, By Applications
10.6.1.3. Market Size and Forecast, By Disease
10.6.1.4 Market Size and Forecast, By End-Use
10.6.2 Canada
10.6.2.1. Market Size and Forecast, By Vector Type
10.6.2.2 Market Size and Forecast, By Applications
10.6.2.3. Market Size and Forecast, By Disease
10.6.2.4 Market Size and Forecast, By End-Use
10.6.3 Mexico
10.6.3.1. Market Size and Forecast, By Vector Type
10.6.3.2 Market Size and Forecast, By Applications
10.6.3.3. Market Size and Forecast, By Disease
10.6.3.4 Market Size and Forecast
11 Europe Viral Vectors And Plasmid DNA Manufacturing Market Analysis and Forecast (2023-2030)
11.1 Introduction
11.2 Europe Viral Vectors And Plasmid DNA Manufacturing Market Share Analysis, By Vector Type
11.3 Europe Viral Vectors And Plasmid DNA Manufacturing Market Size and Forecast, By Applications
11.4 Europe Viral Vectors And Plasmid DNA Manufacturing Market Size and Forecast, By Disease
11.5 Europe Viral Vectors And Plasmid DNA Manufacturing Market Size and Forecast, By End-Use
11.6 Europe Viral Vectors And Plasmid DNA Manufacturing Market Size and Forecast, By Country
11.6.1 Germany
11.6.1.1. Market Size and Forecast, By Vector Type
11.6.1.2 Market Size and Forecast, By Applications
11.6.1.3. Market Size and Forecast, By Disease
11.6.1.4 Market Size and Forecast By End-Use
11.6.2 France
11.6.2.1. Market Size and Forecast, By Vector Type
11.6.2.2 Market Size and Forecast, By Applications
11.6.2.3. Market Size and Forecast, By Disease
11.6.2.4 Market Size and Forecast, By End-Use
11.6.3 UK
11.6.3.1. Market Size and Forecast, By Vector Type
11.6.3.2 Market Size and Forecast, By Applications
11.6.3.3. Market Size and Forecast, By Disease
11.6.3.4. Market Size and Forecast, By End-Use
11.6.4. Russia
11.6.4.1. Market Size and Forecast, By Vector Type
11.6.4.2 Market Size and Forecast, By Applications
11.6.4.3. Market Size and Forecast, By Disease
11.6.4.4 Market Size and Forecast, By End-Use
11.6.5. Italy
11.6.5.1. Market Size and Forecast, By Vector Type
11.6.5.2 Market Size and Forecast, By Applications
11.6.5.3. Market Size and Forecast, By Disease
11.6.5.4 Market Size and Forecast, By End-Use
11.6.6. Spain
11.6.6.1. Market Size and Forecast, By Vector Type
11.6.6.2 Market Size and Forecast, By Applications
11.6.6.3. Market Size and Forecast, By Disease
11.6.6.4 Market Size and Forecast By End-Use
11.6.7. Rest of Europe
11.6.7.1. Market Size and Forecast, By Vector Type
11.6.7.2 Market Size and Forecast, By Applications
11.6.7.3. Market Size and Forecast, By Disease
11.6.7.4 Market Size and Forecast, By End-Use
12 Asia Pacific Viral Vectors And Plasmid DNA Manufacturing Market Analysis and Forecast (2023-2030)
12.1 Introduction
12.2 Asia Pacific Viral Vectors And Plasmid DNA Manufacturing Market Share Analysis, By Vector Type
12.3 Asia Pacific Viral Vectors And Plasmid DNA Manufacturing Market Size and Forecast, By Applications
12.4 Asia Pacific Viral Vectors And Plasmid DNA Manufacturing Market Size and Forecast, By Disease
12.5 Asia Pacific Viral Vectors And Plasmid DNA Manufacturing Market Size and Forecast, By End-Use
12.6 Asia Pacific Viral Vectors And Plasmid DNA Manufacturing Market Size and Forecast, By Country
12.6.1 China
12.6.1.1. Market Size and Forecast, By Vector Type
12.6.1.2 Market Size and Forecast, By Applications
12.6.1.3. Market Size and Forecast, By Disease
12.6.1.4 Market Size and Forecast, By End-Use
12.6.2 Japan
12.6.2.1. Market Size and Forecast, By Vector Type
12.6.2.2 Market Size and Forecast, By Applications
12.6.2.3. Market Size and Forecast, By Disease
12.6.2.4 Market Size and Forecast, By End-Use
12.6.3 India
12.6.3.1. Market Size and Forecast, By Vector Type
12.6.3.2 Market Size and Forecast, By Applications
12.6.3.3. Market Size and Forecast, By Disease
12.6.3.4 Market Size and Forecast By End-Use ,
12.6.4. South Korea
12.6.4.1. Market Size and Forecast, By Vector Type
12.6.4.2 Market Size and Forecast, By Applications
12.6.4.3. Market Size and Forecast, By Disease
12.6.4.4 Market Size and Forecast, By End-Use
12.6.5. Australia
12.6.5.1. Market Size and Forecast, By Vector Type
12.6.5.2 Market Size and Forecast, By Applications
12.6.5.3. Market Size and Forecast, By Disease
12.6.5.4 Market Size and Forecast, By End-Use
12.6.6. New Zealand
12.6.6.1. Market Size and Forecast, By Vector Type
12.6.6.2 Market Size and Forecast, By Applications
12.6.6.3. Market Size and Forecast, By Disease
12.6.6.4 Market Size and Forecast, By End-Use
12.6.7. Singapore
12.6.7.1. Market Size and Forecast, By Vector Type
12.6.7.2 Market Size and Forecast, By Applications
12.6.7.3. Market Size and Forecast, By Disease
12.6.7.4 Market Size and Forecast, By End-Use
12.6.8. Malaysia
12.6.8.1. Market Size and Forecast, By Vector Type
12.6.8.2 Market Size and Forecast, By Applications
12.6.8.3. Market Size and Forecast, By Disease
12.6.8.4 Market Size and Forecast, By End-Use
12.6.9. Rest of Asia
12.6.9.1. Market Size and Forecast, By Vector Type
12.6.9.2 Market Size and Forecast, By Applications
12.6.9.3. Market Size and Forecast, By Disease
12.6.9.4 Market Size and Forecast, By End-Use
13 Latin America Viral Vectors And Plasmid DNA Manufacturing Market Analysis and Forecast (2023-2030)
13.1 Introduction
13.2 Latin America Viral Vectors And Plasmid DNA Manufacturing Market Share Analysis, By Vector Type
13.3 Latin America Viral Vectors And Plasmid DNA Manufacturing Market Size and Forecast, By Applications
13.4 Latin America Viral Vectors And Plasmid DNA Manufacturing Market Size and Forecast, By Disease
13.5 Latin America Viral Vectors And Plasmid DNA Manufacturing Market Size and Forecast, By End-Use
13.6 Latin America Viral Vectors And Plasmid DNA Manufacturing Market Size and Forecast, By Country
13.6.1 Brazil
13.6.1.1. Market Size and Forecast, By Vector Type
13.6.1.2 Market Size and Forecast, By Applications
13.6.1.3. Market Size and Forecast, By Disease
13.6.1.4 Market Size and Forecast, By End-Use
13.6.2 Argentina
13.6.2.1. Market Size and Forecast, By Vector Type
13.6.2.2 Market Size and Forecast, By Applications
13.6.2.3. Market Size and Forecast, By Disease
13.6.2.4 Market Size and Forecast, By End-Use
13.6.3. Colombia
13.6.3.1. Market Size and Forecast, By Vector Type
13.6.3.2 Market Size and Forecast, By Applications
13.6.3.3. Market Size and Forecast, By Disease
13.6.3.4 Market Size and Forecast, By End-Use
13.6.4. Peru
13.6.4.1. Market Size and Forecast, By Vector Type
13.6.4.2 Market Size and Forecast, By Applications
13.6.4.3. Market Size and Forecast, By Disease
13.6.4 Market Size and Forecast, By End-Use
13.6.5. Chile
13.6.5.1. Market Size and Forecast, By Vector Type
13.6.5.2 Market Size and Forecast, By Applications
13.6.5.3. Market Size and Forecast, By Disease
13.6.5.4 Market Size and Forecast, By End-Use
13.6.6. Venezuela
13.6.6.1. Market Size and Forecast, By Vector Type
13.6.6.2 Market Size and Forecast, By Applications
13.6.6.3. Market Size and Forecast, By Disease
13.6.6.4 Market Size and Forecast, By End-Use
13.6.7. rest of Latin America
13.6.7.1. Market Size and Forecast, By Vector Type
13.6.7.2 Market Size and Forecast, By Applications
13.6.7.3. Market Size and Forecast, By Disease
13.6.7.4 Market Size and Forecast, By End-Use
14 Middle East Viral Vectors And Plasmid DNA Manufacturing Market Analysis and Forecast (2023-2030)
14.1 Introduction
14.2 Middle East Viral Vectors And Plasmid DNA Manufacturing Market Share Analysis, By Vector Type
14.3 Middle East Viral Vectors And Plasmid DNA Manufacturing Market Size and Forecast, By Applications
14.4 Middle East Viral Vectors And Plasmid DNA Manufacturing Market Size and Forecast, By Disease
14.5 Middle East Viral Vectors And Plasmid DNA Manufacturing Market Size and Forecast, By End-Use
14.6 Middle East Viral Vectors And Plasmid DNA Manufacturing Market Size and Forecast, By Country
14.6.1. Saudi Arabia
14.6.1.1. Market Size and Forecast, By Vector Type
14.6.1.2 Market Size and Forecast, By Applications
14.6.1.3. Market Size and Forecast, By Disease
14.6.1.4 Market Size and Forecast, By End-Use
14.6.2 UAE
14.6.2.1. Market Size and Forecast, By Vector Type
14.6.2.2 Market Size and Forecast, By Applications
14.6.2.3. Market Size and Forecast, By Disease
14.6.2.4 Market Size and Forecast, By End-Use
14.6.3 Egypt
14.6.3.1. Market Size and Forecast, By Vector Type
14.6.3.2 Market Size and Forecast, By Applications
14.6.3.3. Market Size and Forecast, By Disease
14.6.3.4 Market Size and Forecast, By End-Use
14.6.4 Kuwait
14.6.4.1. Market Size and Forecast, By Vector Type
14.6.4.2 Market Size and Forecast, By Applications
14.6.4.3. Market Size and Forecast, By Disease
14.6.4.4 Market Size and Forecast, By End-Use
14.6.5 South Africa
14.6.5.1. Market Size and Forecast, By Vector Type
14.6.5.2 Market Size and Forecast, By Applications
14.6.5.3. Market Size and Forecast, By Disease
14.6.5.4 Market Size and Forecast, By End-Use
14.6.5 Rest of Middle East & Africa
14.6.6.1. Market Size and Forecast, By Vector Type
14.6.6.2 Market Size and Forecast, By Applications
14.6.6.3. Market Size and Forecast, By Disease
14.6.6.3 Market Size and Forecast, By End-Use
15 Competitive Analysis
15.1 Competition Dashboard
15.2 Market share Analysis of Top Vendors
15.3 Key Development Strategies
16 Company Profiles
16.1 Merck KGaA
16.1.1 Overview
16.1.2 Offerings
16.1.3 Key Financials
16.1.4 Business Segment & Geographic Overview
16.1.5 Key Market Developments
16.1.6 Key Strategies
16.2 FUJIFILM Diosynth Biotechnologies
16.2.1 Overview
16.2.2 Offerings
16.2.3 Key Financials
16.2.4 Business Segment & Geographic Overview
16.2.5 Key Market Developments
16.2.6 Key Strategies
16.3. Thermo Fisher Scientific
16.3.1 Overview
16.3.2 Offerings
16.3.3 Key Financials
16.3.4 Business Segment & Geographic Overview
16.3.5 Key Market Developments
16.3.6 Key Strategies
16.4. Catalent Inc.
16.4.1 Overview
16.4.2 Offerings
16.4.3 Key Financials
16.4.4 Business Segment & Geographic Overview
16.4.5 Key Market Developments
16.4.6 Key Strategies
16.5 Wuxi Biologics
16.5.1 Overview
16.5.2 Offerings
16.5.3 Key Financials
16.5.4 Business Segment & Geographic Overview
16.5.5 Key Market Developments
16.5.6 Key Strategies
16.6 Takara Bio Inc.
16.6.1 Overview
16.6.2 Offerings
16.6.3 Key Financials
16.6.4 Business Segment & Geographic Overview
16.6.5 Key Market Developments
16.6.6 Key Strategies
16.7 Waisman Biomanufacturing
16.7.1 Overview
16.7.2 Offerings
16.7.3 Key Financials
16.7.4 Business Segment & Geographic Overview
16.7.5 Key Market Developments
16.7.6 Key Strategies
16.8 Genezen laboratories
16.8.1 Overview
16.8.2 Offerings
16.8.3 Key Financials
16.8.4 Business Segment & Geographic Overview
16.8.5 Key Market Developments
16.8.6 Key Strategies
16.9 Batavia Biosciences
16.9.1 Overview
16.9.2 Offerings
16.9.3 Key Financials
16.9.4 Business Segment & Geographic Overview
16.9.5 Key Market Developments
16.9.6 Key Strategies
16.10 Miltenyi Biotec GmbH
16.10.1 Overview
16.10.2 Offerings
16.10.3 Key Financials
16.10.4 Business Segment & Geographic Overview
16.10.5 Key Market Developments
16.10.6 Key Strategies
